MedTrace Logo

Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma

NCT00989352 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2009-10-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether combined chemotherapy \[rituximab plus high dosage methotrexate, lomustine, and procarbazine\] followed by maintenance therapy with procarbazine is effective in the treatment of cerebral Non Hodgkin lymphoma \[PCNSL\] in patients \> 65 years.

Conditions

  • Primary Non Hodgkin Lymphoma of the Central Nervous System

Interventions

DRUG

Methotrexate

3g/m² i.v. max. 9 times

DRUG

Lomustine

110 mg/m² p.o., max. 3 times

DRUG

Procarbazine

60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times

DRUG

Rituximab

375 mg/m² i.v., max. 10 times

Sponsors & Collaborators

  • Universitätsklinikum Köln

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • University Hospital Heidelberg

    collaborator OTHER

  • University Hospital Ulm

    collaborator OTHER

  • University Hospital Freiburg

    lead OTHER

Principal Investigators

  • Gerald Illerhaus, PD Dr. · University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-06-30
Completion
2011-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00989352 on ClinicalTrials.gov